Double-phase 99mTc-sestamibi scintimammography and trans-scan in diagnosing breast cancer

Journal of Nuclear Medicine

Volumn 40, Issue 3, 1999, Pages 376-380

  Melloul, Moshe ^a   Paz, Adrian ^b   Ohana, Gil ^b   Laver, Ora ^b   Michalevich, David ^b   Koren, Rumelia ^b   Wolloch, Yaakov ^b   Rivka, Gal ^b  

^a HASHARON HOSPITAL   (Israel)

^b NONE

Author keywords

99mTc sestamibi scintimammography; Breast cancer; Trans scan

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMAGING SYSTEM; IMPEDANCE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PALPATION; PRIORITY JOURNAL; SCINTIMAMMOGRAPHY; BREAST; BREAST TUMOR; CASE REPORT; ELECTRODIAGNOSIS; MIDDLE AGED; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BREAST; BREAST NEOPLASMS; ELECTRIC IMPEDANCE; ELECTRODIAGNOSIS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI;

EID: 0032588265     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer. N Engl J Med. 1992;327:319-328.
2. Pollei SR, Mettler FA, Bartow SA, Moradian G, Moskowitz M. Occult breast cancer: prevalence and radiographic detectability. Radiology. 1987;163:459-462.
3. Waxman AD, Ramanna L, Memsic LD. et al. Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med. 1993;34:18-23.
4. Tiling R, Sommer H, Pechmann M, et al. Comparison of technetium-99m-sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions. J Nucl Med. 1997;38:58-62.
5. Palmedo H, Schomburg A, Grunwald F, Mallmann P, Krebs D, Biersack HJ. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med. 1996;37:626-630.
6. Villanueva-Meyer J, Leonard MH Jr. Briscoe E, et al. Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med. 1996;37:926-930.
7. Khalkhali I, Cutrone J, Mena I, et al. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med. 1995;36:1784-1789.
8. Alonso JC, Soriano A, Zarca MA, Guerra P, Alcazar R, Molino C. Breast cancer detection with sestamibi-Tc-99m and T1-201 radionuclides in patients with non-conclusive mammography. Anticancer Res. 1997;17:1661-1665.
9. 99mTc-MIBI prone scintimammography in patients with high and intermediate risk mammography. Anticancer Res. 1997;17:1635-1638.
10. Piperno G, Frei EH, Moshitzky M. Breast cancer screening by impedance measurements. Front Med Biol Eng. 1990;2:111-117.
11. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg. 1994;178:491-497.
12. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med. 1995;36:1758-1765.
13. Kao CH, Wang SJ, LiuTJ. The use of technetium-99m-methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med. 1994;21:432-436.
14. Kopans DB. The positive predictive value of mammography. AJR. 1992;158:521-526.
15. Ambrus E, Rajtar M, Ormandi K, et al. Value of 99m-Tc MIBI and 99m-Tc(V) DMSA scintigraphy in evaluation of breast mass lesions. Anticancer Res. 1997;17:1599-1605.
16. 99mTc-MIBI mammoscintigraphy of breast masses: early and delayed imaging. Nucl Med Commun. 1995;16:150-156.
17. Abrus E, Rajtar M, Ormandi K, et al. Value of 99m-Tc MIBI and 99m-Tc(V) DMSA scintigraphy in evaluation of breast mass lesions. Anticancer Res. 1997;17:1599-1605.
18. Surowiec AJ, Stuchly SS, Barr JB, Swarup A. Dielectric properties of breast carcinoma and the surrounding tissues. IEEE Trans Biomed Eng. 1988;35:257-263.